{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:39:49Z","timestamp":1782959989976,"version":"3.54.5"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Recent trials have shown the efficacy of new drugs for the medical therapy of heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduced hospitalizations for heart failure (HF), HF events, and cardiovascular death in patients with HFrEF or hospitalized for HF. Iron repletion with ferric carboxymaltose (FCM) improved symptoms, functional capacity, and quality of life in chronic HFrEF patients, and decreased the risk of subsequent HF hospitalizations in subjects with acutely decompensated HF. New-generation potassium binders may allow initiation and up-titration of renin\u2013angiotensin\u2013aldosterone system inhibitors (RASis). Lastly, the guanylate cyclase stimulator vericiguat and the myosin activator omecamtiv mecarbil reduced the primary endpoint in two major controlled trials. These results open novel pathways for the treatment of HFrEF. This review discusses new opportunities of an individualized approach to HFrEF pharmacotherapy, where new compounds expand a spectrum of drugs that target primarily neuroendocrine activation. SGLT2i can be safely applied once daily at a fixed dose to the vast majority of patients with HFrEF, including those with moderate renal dysfunction and\/or systolic blood pressure as low as 95\u2013100\u2009mmHg. Additional medications are suitable for more specific phenotypes, with ivabradine providing benefit in patients with sinus rhythm and heart rates \u226570 b.p.m., FCM in the presence of iron deficiency, and potassium-lowering agents to implement RASi when hyperkalaemia occurs. Vericiguat and omecamtiv mecarbil also have potential for tailored approaches towards the haemodynamic status. Thus, a new era is starting for a more personalized medical treatment of HFrEF.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvab033","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T11:12:19Z","timestamp":1621941139000},"page":"539-546","source":"Crossref","is-referenced-by-count":29,"title":["Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-7287","authenticated-orcid":false,"given":"Pietro","family":"Ameri","sequence":"first","affiliation":[{"name":"Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, IRCCS Italian Cardiology Network, Genova, Italy"},{"name":"Department of Internal Medicine, University of Genova, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Bertero","sequence":"additional","affiliation":[{"name":"Comprehensive Heart Failure Center (CHFC), University Clinic W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3694-4559","authenticated-orcid":false,"given":"Christoph","family":"Maack","sequence":"additional","affiliation":[{"name":"Comprehensive Heart Failure Center (CHFC), University Clinic W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Teerlink","sequence":"additional","affiliation":[{"name":"Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6868-4248","authenticated-orcid":false,"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, IRCCS San Raffaele Pisana, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8568","authenticated-orcid":false,"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology Unit, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"2021110402482932800_pvab033-B1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jchf.2015.03.013","article-title":"Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials","volume":"3","author":"Rush","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2021110402482932800_pvab033-B2","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/ejhf.1594","article-title":"Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis","volume":"21","author":"Jones","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2021110402482932800_pvab033-B3","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"2021110402482932800_pvab033-B4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"2021110402482932800_pvab033-B5","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2021110402482932800_pvab033-B6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2021110402482932800_pvab033-B7","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2021110402482932800_pvab033-B8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2021110402482932800_pvab033-B9","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2021110402482932800_pvab033-B10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"2021110402482932800_pvab033-B11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"2021110402482932800_pvab033-B12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2021110402482932800_pvab033-B13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2021110402482932800_pvab033-B14","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"2021110402482932800_pvab033-B15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2018.09.036","article-title":"Meta-analysis of effects of digoxin on survival in patients with atrial fibrillation or heart failure: an update","volume":"123","author":"Vamos","year":"2019","journal-title":"Am J Cardiol"},{"key":"2021110402482932800_pvab033-B16","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"20","author":"Komajda","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2021110402482932800_pvab033-B17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2021110402482932800_pvab033-B18","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2021110402482932800_pvab033-B19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s11739-019-02060-0","article-title":"Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure","volume":"14","author":"Bertero","year":"2019","journal-title":"Intern Emerg Med"},{"key":"2021110402482932800_pvab033-B20","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"2021110402482932800_pvab033-B21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF Registry","volume":"7","author":"Brunner-La Rocca","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2021110402482932800_pvab033-B22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jchf.2020.04.019","article-title":"Care gaps in adherence to heart failure guidelines: clinical inertia or physiological limitations?","volume":"8","author":"Jarjour","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2021110402482932800_pvab033-B23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/ejhf.1532","article-title":"Sacubitril\/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency\/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world","volume":"21","author":"Kapelios","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2021110402482932800_pvab033-B24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ejhf.1459","article-title":"Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"21","author":"Komajda","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2021110402482932800_pvab033-B25","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"2021110402482932800_pvab033-B26","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"2021110402482932800_pvab033-B27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"2021110402482932800_pvab033-B28","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1093\/eurheartj\/ehy596","article-title":"Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology","volume":"39","author":"Maack","year":"2018","journal-title":"Eur Heart J"},{"key":"2021110402482932800_pvab033-B29","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2021110402482932800_pvab033-B30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2021110402482932800_pvab033-B31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2021110402482932800_pvab033-B32","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2021110402482932800_pvab033-B33","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"2021110402482932800_pvab033-B34","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.1536","article-title":"Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial","volume":"21","author":"Packer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2021110402482932800_pvab033-B35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status\u2014results from the EMPEROR-Reduced Trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"2021110402482932800_pvab033-B36","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2021110402482932800_pvab033-B37","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/ejhf.2026","article-title":"Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure","volume":"22","author":"Seferovic","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2021110402482932800_pvab033-B38","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/eurheartj\/ehq158","article-title":"Iron deficiency: an ominous sign in patients with systolic chronic heart failure","volume":"31","author":"Jankowska","year":"2010","journal-title":"Eur Heart J"},{"key":"2021110402482932800_pvab033-B39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ajcn\/79.3.437","article-title":"Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women","volume":"79","author":"Brownlie","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"2021110402482932800_pvab033-B40","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/ejhf.640","article-title":"Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis","volume":"19","author":"Melenovsky","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2021110402482932800_pvab033-B41","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"2021110402482932800_pvab033-B42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"2021110402482932800_pvab033-B43","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"2021110402482932800_pvab033-B44","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2021110402482932800_pvab033-B45","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2021110402482932800_pvab033-B46","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ejhf.1860","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2021110402482932800_pvab033-B47","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"2021110402482932800_pvab033-B48","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","article-title":"Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)","volume":"41","author":"Serenelli","year":"2020","journal-title":"Eur Heart J"},{"key":"2021110402482932800_pvab033-B49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"2021110402482932800_pvab033-B50","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study","volume":"8","author":"Ezekowitz","year":"2020","journal-title":"JACC Heart Fail"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvab033\/38709422\/pvab033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/6\/539\/41073003\/pvab033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/6\/539\/41073003\/pvab033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T02:49:30Z","timestamp":1635994170000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/7\/6\/539\/6284961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,5,26]]},"published-print":{"date-parts":[[2021,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvab033","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2021,5,26]]}}}